FORMER KENNEDY STAFFER ALLAN FOX AND EX-FDA LAWYER ALAN BENNETT
FORMER KENNEDY STAFFER ALLAN FOX AND EX-FDA LAWYER ALAN BENNETT are starting a separate health care law practice in Washington. The new firm, Fox, Weinberg & Bennett, will specialize in health related regulatory, reimbursement and environmental issues. Fox and Bennett were previously with the Washington office of New York's Kaye, Scholer, Fierman, Hays & Handler. The new firm's environmental expertise will come from David Weinberg, who has been with the Washington office of an Ohio firm, Porter, Wright, Morris & Arthur. Fox served as a legislative aid to Sen. Kennedy (D-Mass.) during the mid-1970's and was involved in the Senate Labor and Human Resources Cmte.'s hearings on drug industry practices. After serving with Kennedy, Fox became Chief of Staff to former Sen. Javits (R-NY) from 1977-1979. He has been in private practice since 1980. As an associate chief counsel, Bennett served in FDA's General Counsel Office for over three years under Peter Hutt and his successor as FDA Chief Counsel Richard Merrill. Following his tenure at FDA, Bennett moved to Capitol Hill as a legislative aid to Sen. Javits from 1977-1981, and then to private practice with Kaye, Scholer. At Kaye, Scholer, Fox and Bennett were involved in the legislative negotiations leading to passage two years ago of the patent restoration/ANDA law. Last year, the lawyers represented clients concerned with the Reye's Syndrome labeling initiative. The new firm's health related client mix includes drug and device firms, universities involved with biomedical research, and hospitals and health provider organizations effected by reimbursement policies set by the Dept. of Health and Human Services. The firm's expertise in reimbursement issues is supplied by Sam Turner, a former Deputy General Counsel at HHS who also served as a special assistant to the Health Care Financing Administration's legal office.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth